| Name | Title | Contact Details |
|---|
CoreLink Administrative Solutions was launched on January 1, 2009, as a new concept in health care benefits technology. We provide the technology that allows multiple companies to share common core systems and services, resulting in significant cost savings, gains in efficiency and improved capabilities to provide enhanced services. CoreLink is a long-term IT investment funded by Blue Cross Blue Shield of Nebraska and Blue Cross Blue Shield of North Dakota. Working together, the technology experts have built an infrastructure capitalizing on the strengths and experience of both Plans. This investment provides the means to efficiently address the ongoing changes in the health care environment and challenges posed by regulatory requirements, which can add significant costs to Plan operations.
DecisionLine Clinical Research is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PreclinPharma is a Englewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
University Hospitals, one of the nation`s leading health care systems, focuses on providing compassionate, quality medical care to patients at convenient locations throughout Northeast Ohio.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.